Combination Immunotherapy and Chemotherapy Used in GI Cancers

Dosing Schedule Factors into Chemo/ICI Choice in Upper GI Cancer

During a live event, Yelena Y. Janjigian, MD, moderated a discussion on which frontline treatment to give a 60-year-old patient with stage IV gastric adenocarcinoma.

Understanding the Use of Nivolumab in the Current Upper GI Landscape

David Zhen, MD, discussed the relevance of nivolumab in the upper gastrointestinal cancer population.

Targeted Therapy Options for Gastric/GEJ Cancers Expand

Ronan J. Kelly, MD, MBA, discusses the targeted therapy options that have become available for patients with gastric, esophageal, and gastroesophageal junction cancers.

Five-Year Data Confirm Benefit of Nivolumab in Upper GI Cancer

David B. Zhen, MD, discusses the results of the phase 3 CheckMate 649 trial in patients with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.

KEYNOTE-859 Outcomes Influence NCCN Guidelines on Pembrolizumab in Upper GI Cancer

During a Case-Based Roundtable® event, David Zhen, MD, discussed how treatment of upper gastrointestinal cancer with pembrolizumab and chemotherapy is impacted by PD-L1 composite positive score, in the second article of a 2-part series.

PD-L1 Status Shapes Choice of Using Nivolumab in Upper GI Cancer

During a Case-Based Roundtable® event, David Zhen, MD, discussed the issue of treating patients with upper gastrointestinal cancer with a PD-L1 composite positive score less than 5 with nivolumab vs chemotherapy alone, in the first article of a 2-part series.

PD-L1 Provides Valid Biomarker for Nivolumab/Chemo in Gastric Cancer

In a discussion with Targeted Oncology, Michael Gibson, MD, PhD, discusses the benefits of using a patient’s PD-L1 combined positive score to determine if they are given nivolumab and chemotherapy to treat their gastric cancer.

PD-L1 CPS Plays Role in Selecting Treatment for Gastric Cancer

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed the addition of nivolumab to chemotherapy for patients with gastric/gastroesophageal junction cancer based on PD-L1 status. This is the second of 2 articles based on this event.

Managing Adverse Events of Nivolumab/Chemotherapy for Gastric/GEJ Cancers

During a Targeted Oncology case-based roundtable event, Syma Iqbal, MD, discussed with participants their impressions of the CheckMate 649 chemoimmunotherapy regimen for patients with gastric/gastroesophageal junction cancers. This is the first of 2 articles based on this event.

CheckMate 649 Study in GI Cancers Shows Survival Benefit for Nivolumab/Chemotherapy

Jaffer A. Ajani, MD, discusses the design and results of the CheckMate 649 study of nivolumab, ipilimumab, and chemotherapy for gastric cancers.